- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01934855
Tumor Motion Management in Radiotherapy Using 4D-MRI
Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI
The main goal of this research is to characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in clinics. Specifically, the investigators hypothesize that dynamic MRI (Magnetic Resonance Imaging) obtained over a temporal duration consistent with radiotherapy treatments will provide spatio-temporal information of both the tumor and surrogate, and therefore can serve as a means to assess the quality of the tumor motion tracking with the surrogate. To test this hypothesis, the investigators specifically propose to 1) track and characterize the tumor and surrogate motion with 4D (4 dimensional)-MRI and 2) evaluate surrogate-based motion tracking in a cohort of patients with thoracic tumors.
External and internal surrogate-based strategies commonly used in clinics have not been appropriately validated. With the increasing adaptation of these surrogate methods for motion management, the proposed research addresses these urgent issues in clinical radiotherapy while providing a means to achieve patient-specific motion management.
Study Overview
Status
Conditions
Detailed Description
Respiration-induced patient motion has become a major obstacle for achieving high-precision radiotherapy of cancers especially in the thorax and upper abdomen. As the target is continuously moving, an additional margin has to be added to the clinical target volume to compensate for the uncertainty in the tumor and organ motion, causing toxicity to the normal tissue and limiting the dose delivered to the target. To account for the tumor motion, surrogate tracking methods are commonly used in clinics during radiotherapy. However, the relationship between the surrogate and tumor motion is hard to generalize as it depends on individual patients, tumor location, treatment fractions, and sometimes shows complex patterns or transient, unpredictable changes. Hence, there is an urgent need to better scrutinize the current surrogate-based motion management strategies. Moreover, the most robust motion management strategy for the given patient should be determined in the pre-treatment setting but the investigators currently lack a sufficient tool to provide this information.
4D-CT is typically used to characterize the tumor motion over the course of the radiotherapy. However, 4D-CT is an oversimplified snapshot representation of a single-breathing cycle with low soft tissue contrast while imparting a considerable amount of radiation dose to the patient. Consequently, the limitations of 4D-CT prevent applicability in acquiring information over timescales that represent a treatment session. MRI is highly advantageous as it is non-ionizing and provides excellent soft tissue contrast. Although real-time 3D dynamic MRI is limited by low image quality and temporal resolution, 2D dynamic MRI techniques have high fidelity and spatio-temporal resolution requisite for real-time tracking of the moving target. Furthermore, a respiration-correlated 4D-MRI can be reconstructed from multi-slice 2D dynamic MR images, enabling volumetric image processing and analysis. Therefore, 4D-MRI is an attractive solution to address breathing motion and tumor tracking obstacles in radiotherapy.
The main goal of this research is to characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in clinics. Specifically, the investigators hypothesize that dynamic MRI obtained over a temporal duration consistent with radiotherapy treatments will provide spatio-temporal information of both the tumor and surrogate, and therefore can serve as a means to assess the quality of the tumor motion tracking with the surrogate. To test their hypothesis, the investigators specifically propose to 1) track and characterize the tumor and surrogate motion with 4D-MRI and 2) evaluate surrogate-based motion tracking in a cohort of patients with thoracic tumors.
External and internal surrogate-based strategies commonly used in clinics have not been appropriately validated. With the increasing adaptation of these surrogate methods for motion management, the proposed research addresses these urgent issues in clinical radiotherapy while providing a means to achieve patient-specific motion management.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically-confirmed primary lung cancer (non-small cell OR small cell)
- Plan to undergo external radiation treatment of lung cancer
Exclusion Criteria:
- Patients who cannot undergo MRIs.
- Patients who have a cardiac device or other electronic or metal implant
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor motion characterization during radiation therapy
Time Frame: 1 year
|
To characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in radiotherapy.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of tumor and surrogate motion
Time Frame: 1 year
|
Tumor and surrogate motion will be quantified by measuring the displacements from their end-exhale positions.
Since the tumor may deform during motion, we will not only consider the trajectories of the center of mass but also the tumor borders.
The tumor position as a function of the surrogate position will be analyzed along each moving direction.
Pearson correlation coefficients and the sum of squared residual errors based on a regression analysis will be computed to provide a quantitative measure of the correlation between the surrogate and tumor positions.
To measure the tumor deformation, correlations of the motion between the SI borders, AP borders, LR borders will also be computed.
Although lung tumor likely does not significantly deform, this analysis will be useful for tumors that may deform significantly during motion.
The motion under the different breathing patterns will be analyzed separately, and compared to each other.
|
1 year
|
Sensitivity and specificity of gating
Time Frame: 1 year
|
Respiratory gating is one predominant technique for managing respiratory motion.
Gating attempts to minimize normal tissue dose by delivering radiation during a portion of the respiratory cycle where the respiratory state is typically determined from an external surrogate as an optical signal.
We will use different gating boundaries, e.g.
10%, 20% of the surrogate motion range (from mean exhale to mean inhale) on each axes as commonly used in clinical practice.
Sensitivity and specificity of the gating will be computed by comparing the portion of time the surrogate is below/above the gating boundary and that the tumor is below/above the gating boundary.
|
1 year
|
Pre- and intra-treatment motion variability
Time Frame: 1 year
|
MRI scans of the patient will be acquired pre- and intra-treatment.
Tumor motion variability will be computed between these two scans.
We will evaluate the correlation of the target location captured at different time points by computing target volume overlap and systematic volume shift.
We will also analyze the tumor position as a function of the surrogate position for both pre- and intra-treatment scans, and will investigate how well these two distributions match.
To quantitatively measure the differences, we will compute various statistical similarity measures such as correlation coefficient and mutual information.
We will also calculate pre-treatment margins to account for the tumor motion using the pre-treatment retrospective 4D-MRI reconstruction, and calculate the portion of treatment time the tumor moves within or outside the specified margins during the successive scans.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Russell Hales, M.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- J1370
- NA_00085958 (Other Identifier: Johns Hopkins Institutional Review Board)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States